20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The following is a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks that hit 52-week highs on Dec. 26.)
- Aimmune Therapeutics Inc (NASDAQ:AIMT)
- Allergan plc (NYSE:AGN)
- Applied Genetic Technologies Corp (NASDAQ:AGTC)
- Aprea Therapeutics Inc (NASDAQ:APRE)
- Arvinas Inc (NASDAQ:ARVN)
- Ascendis Pharma A/S (NASDAQ:ASND)
- Audentes Therapeutics Inc (NASDAQ:BOLD)
- Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
- Avenue Therapeutics Inc (NASDAQ:ATXI)
- Axsome Therapeutics Inc (NASDAQ:AXSM)
- Cassava Sciences Inc (NASDAQ:SAVA)
- Clearside Biomedical Inc (NASDAQ:CLSD)
- Cue Biopharma Inc (NASDAQ: CUE
- Dermira Inc (NASDAQ:DERM)
- DURECT Corporation (NASDAQ:DRRX)
- Eiger Biopharmaceuticals Inc (NASDAQ:EIGR)
- Esperion Therapeutics Inc (NASDAQ:ESPR)
- Exagen Inc (NASDAQ:XGN)
- Fortress Biotech (NASDAQ:FBIO)
- Fulcrum Therapeutics Inc (NASDAQ:FULC)
- Global Blood Therapeutics Inc (NASDAQ:GBT)
- Horizon Therapeutics PLC (NASDAQ:HZNP)
- IGM Biosciences Inc (NASDAQ:IGMS)
- Immunomedics, Inc. (NASDAQ:IMMU) (announced resubmission of BLA for sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
- Jounce Therapeutics Inc (NASDAQ:JNCE)
- Karyopharm Therapeutics Inc (NASDAQ:KPTI)
- Kodiak Sciences Inc (NASDAQ:KOD)
- Mirati Therapeutics Inc (NASDAQ:MRTX)
- Molecular Templates Inc (NASDAQ:MTEM)
- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
- Myokardia Inc (NASDAQ:MYOK)
- NeoGenomics, Inc. (NASDAQ:NEO)
- NewLink Genetics Corp (NASDAQ:NLNK)
- Novan Inc (NASDAQ:NOVN)
- Oncolytics Biotech, Inc. (NASDAQ:ONCY)
- Ovid Therapeutics Inc (NASDAQ:OVID)
- Oyster Point Pharma Inc (NASDAQ:OYST)
- Phathom Pharmaceuticals Inc (NASDAQ:PHAT)
- Profound Medical Corp (NASDAQ:PROF)
- Recro Pharma Inc (NASDAQ:REPH)
- SpringWorks Therapeutics Inc (NASDAQ:SWTX)
- Synthorx Inc (NASDAQ:THOR)
- TG Therapeutics Inc (NASDAQ:TGTX)
- XOMA Corp (NASDAQ:XOMA)
- Zimmer Biomet Holdings Inc (NYSE:ZBH)
Down In The Dumps
(Biotech stocks that hit 52-week lows on Dec. 26.)
- Akorn, Inc. (NASDAQ:AKRX)
- Ekso Bionics Holdings Inc (NASDAQ:EKSO)
- MediciNova, Inc. (NASDAQ:MNOV)
- Stealth BioTherapeutics Corp (NASDAQ:MITO)
- Ritter Pharmaceuticals Inc (NASDAQ:RTTR)
- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) (announced negative Phase 2 data for investigational drug to treat non-small cell lung cancer patients with a particular mutation)
- Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) (announced halting of a mid-phase study of hepatitis B virus therapy due to liver injury)
Stocks In Focus
Flexion's Zilretta Granted Label Expansion For Osteoarthritis Knee Pain
Flexion Therapeutics Inc (NASDAQ:FLXN) said the FDA approved its sNDA for a label expansion for Zilretta in osteoarthritis knee pain.
"ZILRETTA is an invaluable non-opioid option for managing chronic OA knee pain, and it is encouraging to see a new product label that better informs clinical decision making," Dr. John Richmond, a clinician, said in a statement.
Originally, the FDA had set a PDUFA action date of Oct. 14, which was extended by three months.
The stock was trading 24.85% higher at $23.94 in Friday's premarket session.
Astellas Buys Immuno-Oncology Company Xyphos For Up To $665M
Japanese pharma company Astellas Pharma Inc. (NASDAQ:ALPMY) announced the acquisition of privately held Xyphos Biosciences, which will give the former access to the latter's proprietary ACCEL tech platform, as well as immuno-oncology talent to help develop new ways to mobilize, target and control immune cells.
"The innovative technology in development at Xyphos fits perfectly in advancing our immuno-oncology strategy to create and deliver value for patients," Astellas CEO Kenji Yasukawa said in a statement.
"Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology."
With the $120 million paid by Astellas at the time of closing and the potential future development milestone payments, the deal is valued at up to $665 million.
Related Links:
10 Biotech M&A Targets Under The Scanner For 2020
A Perspective On Biopharma's Record M&A Run In 2019
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!